الفهرس 
Table of contentsOnly 14 pages are availabe for public view
 |  | from | 146 |  |  |
| | | from | 146 | | |
Abstract
Ovarian cancer is the most common lethal gynecological malignancy and represents a major cause of morbidity and mortality among female patients. The increasing incidence for serous ovarian carcinoma among the Egyptian population is a considerable health problem deserving research. In general, serous ovarian carcinoma usually is diagnosed at late stages. Its nonspecific symptoms that divert the patient and the physician away from the ovary and absence of effective screening strategy are the main causes. HGSOC, is the dominant and most lethal subtype characterized by marked genomic instability with defects in DNA repair pathways. It has more aggressive behavior, rapid rate of development, dissemination and associated with a poor prognosis. As it has marked heterogenous molecular pathways and different clinical behavior, attention should be paid during applying treatment that one treatment for all cases of HGSOC is no longer effective. Gene expression profiling studies were done through TCGA research network team on HGSOC cases, and demonstrated four molecular subtypes for HGSOC C1, C2, C4 and C5; each of them has a significant correlation to patient outcome. Mesenchymal subtype (C1) is marked by a reactive stromal signature and associated with a poor overall prognosis. Immunoreactive subtype (C2) is characterized by tumor infiltrating lymphocytes (TILs) with a characteristic good overall survival. Differentiated subtype (C4) has a gene expression signature closely related to C2 and also associated with a better prognosis. Proliferative subtype (C5) found to have a poor overall survival. Limited studies about this recently established molecular classification are available especially in addressing the relation between this classification and histopathological features on one hand and with patient prognosis on the other hand. The current study suggested to use immunohistochemistry (IHC) as a less expensive, more available and more easy handled method to raise the hypothesis that histopathology and IHC may help to subtype HGSOC into prognostically distinct groups. It is needed to find indicators that can detect HGSOC patients with good prognoses who can get benefit from conventional therapy and also differentiate them from others who need more aggressive treatment regimens or targeted therapy administration. This retrospective study was conducted on 85 specimens for cases of HGSOC, retrieved from archives of surgical pathology lab at Oncology Centre & University Hospitals; Mansoura University, Egypt. The data of 85 patients with high grade serous ovarian carcinoma who were treated during the period from 2010 to 2017 at Clinical Oncology and Nuclear Medicine Department were revised.